GSK reveals speaker, consulting fees

Share this article:
Deirdre Connelly
Deirdre Connelly
GlaxoSmithKline said it paid nearly $15 million in fees in the second quarter to US healthcare professionals for speaking and consulting services.

A 121-page report posted yesterday by the Anglo firm highlights amounts given to 3,700 KOLs and other providers. Payees received $3,909 on average. The highest-paid recipient on the list was a specialist in rheumatology-allergy and immunology at Brigham and Women's Hospital in Boston, who received $99,375.

Such fees are often made in exchange for talks or consulting services in therapeutic areas that coincide with a company's marketed products. GSK's asthma/COPD treatment Advair Diskus was the fourth best-selling drug in the US in 2008, according to IMS Health.

Deirdre Connelly, GSK's president North America pharmaceuticals, said: “These are professionals who should be fairly compensated for the services and expertise they provide. There are strict guidelines about how we work together.”

GSK and other drug firms have been drawing back the curtain on payments to doctors ahead of legislation that could make such disclosures mandatory. Both the healthcare reform bill that cleared the House earlier this year and the Senate bill nearing passage include language meant to increase public disclosure of payments.

Earlier this year, Eli Lilly became the first major drug company to provide a detailed list of consulting and speaker fees when it posted its faculty registry, disclosing $22 million in first-quarter compensation paid to almost 3,400 US physicians and other healthcare professionals.

Next up was Merck, which said it shelled out $3 million in speaker fees to US doctors during the second quarter. Pfizer has also pledged to publicize amounts given to support influential doctors.

Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.